medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2022-15-20-25medalphabet-2690Research ArticleСтатьиРевматологические проявления постковидного синдрома (обзор литературы)Rheumatological manifestations of post-COVID syndrome (literature review)https://orcid.org/0000-0002-1833-5357АроноваЕ. С.AronovaE. S.

Аронова Евгения Сергеевна, к.м.н., н.с. лаборатории изучения коморбидных инфекций и вакцинопрофилактики

Москва

Aronova Evgenia S., PhD Med, researcher at Laboratory for the Study of Comorbid Infections and Vaccination

Moscow

eugpozd@mail.ruhttps://orcid.org/0000-0001-7091-2054БеловБ. С.BelovB. S.

Белов Борис Сергеевич, д.м.н. зав. лабораторией изучения коморбидных инфекций и вакцинопрофилактики

Москва

Belov Boris S., DM Sci (habil.), head of Laboratory for the Study of Comorbid Infections and Vaccination

Moscow

https://orcid.org/0000-0002-0928-3911ГридневаГ. И.GridnevaG. I.

Гриднева Галина Игоревна, к.м.н., н.с. лаборатории изучения коморбидных инфекций и вакцинопрофилактики

Москва

Gridneva Galina I., PhD Med, researcher at Laboratory for the Study of Comorbid Infections and Vaccination

Moscow

ФГБНУ «Научно-исследовательский институт ревматологии имени В. А. Насоновой»РоссияV. A. Nasonova Research Institute of RheumatologyRussian Federation202225072022015Ревматология в общей врачебной практике» (1)2025Copyright © Аронова Е.С., Белов Б.С., Гриднева Г.И., 20222022Аронова Е.С., Белов Б.С., Гриднева Г.И.Aronova E.S., Belov B.S., Gridneva G.I.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2690

К настоящему времени основной резонанс вызывают исследования так называемого постковидного синдрома, который может возникать даже у пациентов, перенесших COVID-19 в легкой или среднетяжелой форме. В представленном обзоре приведена историческая справка о возникновении этого термина, рассмотрены наиболее часто встречающиеся ревматологические проявления постковидного синдрома, в том числе артралгия, сыпь, перниоз, одышка, усталость, фибромиалгия, образование аутоантител и маркеров системного воспаления. В обзоре приведены также актуальные взгляды на лечение постковидного синдрома. Авторы подчеркивают необходимость дифференциальной диагностики между ревматологическими проявлениями постковидного синдрома и дебютом ревматического заболевания, возникшего после перенесенного COVID-19, и обосновывают мультидисциплинарный подход к методам терапии.

To date, the main resonance is caused by studies of the so-called post-COVID syndrome, which can occur even in patients who have had mild or moderate COVID-19. The present review provides a historical background on the origin of this term, considers the most common rheumatological manifestations of post-COVID syndrome, including arthralgia, rash, perniosis, dyspnea, fatigue, fibromyalgia, the formation of autoantibodies and markers of systemic inflammation. The review also provides current views on the treatment of post-COVID syndrome. The authors emphasize the need for differential diagnosis between rheumatological manifestations of post-COVID syndrome and the onset of rheumatic disease after COVID-19, and substantiate a multidisciplinary approach to therapy methods.

COVID-19иммуновоспалительные ревматические заболеванияпостковидный синдромлонг-ковидартралгияфибромиалгияCOVID-19long COVIDimmunoinflammatory rheumatic diseasepost COVID-19 conditionpost-COVID-19 syndromearthralgiafibromyalgiaReferencesBliddal S., Banasik K., Pedersen O. B. et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep. 2021. 11. 13153. DOI: 10.1038/s41598–021–92045-x.Bliddal S., Banasik K., Pedersen O. B. et al. Acute and persistent symptoms in non-hospitalized PCR-confirmed COVID-19 patients. Sci Rep. 2021. 11. 13153. DOI: 10.1038/s41598–021–92045-x.Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1/06/2022. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6january2022Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1/06/2022. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/6january2022Perego E, Callard F, Stras L, et al. Why we need to keep using the patient made term “Long Covid”. Available at: https://blogs.bmj.com/bmj/2020/10/01/whywe-need-to-keep-using-the-patient-made-term-long-covid/ (1 October 2020)Perego E, Callard F, Stras L, et al. Why we need to keep using the patient made term “Long Covid”. Available at: https://blogs.bmj.com/bmj/2020/10/01/whywe-need-to-keep-using-the-patient-made-term-long-covid/ (1 October 2020)Patients’ experiences of “longcovid” are missing from the NHS narrative. Available at: https://blogs.bmj.com/bmj/2020/07/10/patients-experiences-of-long-covid-are-missing-from-the-nhs-narrative/Patients’ experiences of “longcovid” are missing from the NHS narrative. Available at: https://blogs.bmj.com/bmj/2020/07/10/patients-experiences-of-long-covid-are-missing-from-the-nhs-narrative/Covid - 19: What do we know about “long covid”? BMJ 2020; 370: m2815. https://doi.org/10.1136/bmj.m2815Covid - 19: What do we know about “long covid”? BMJ 2020; 370: m2815. https://doi.org/10.1136/bmj.m2815National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. Available at: https://www.nice.org.uk/guidance/ng188 (18 December 2020)National Institute for Health and Care Excellence. COVID-19 rapid guideline: managing the long-term effects of COVID-19. NICE guideline [NG188]. Available at: https://www.nice.org.uk/guidance/ng188 (18 December 2020)Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–615. DOI: 10.1038/s41591–021–01283-zNalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med 2021; 27: 601–615. DOI: 10.1038/s41591–021–01283-zAl-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594: 259–264. DOI: 10.1038/s41586–021–03553–9.Al-Aly Z., Xie Y., Bowe B. High-dimensional characterization of post-acute sequelae of COVID-19. Nature 2021; 594: 259–264. DOI: 10.1038/s41586–021–03553–9.Phillips S., Williams M. A. Confronting our next national health disaster – long-haul Covid. N Engl J Med 2021; 385: 577–579. DOI: 10.1056/NEJMp2109285.Phillips S., Williams M. A. Confronting our next national health disaster – long-haul Covid. N Engl J Med 2021; 385: 577–579. DOI: 10.1056/NEJMp2109285.World Health Organisation (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition_Clinical_case_definition-2021.1.World Health Organisation (WHO). A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition_Clinical_case_definition-2021.1.Parums D. V. Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care. Med Sci Monit. 2021; 27: e933446. DOI: 10.12659/MSM.933446.Parums D. V. Editorial: Long COVID, or Post-COVID Syndrome, and the Global Impact on Health Care. Med Sci Monit. 2021; 27: e933446. DOI: 10.12659/MSM.933446.Ghosn J., Piroth. L., Epaulard O., et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. 2021 Jul; 27 (7): 1041. e1–1041.e4. DOI: 10.1016/j.cmi.2021.03.012.Ghosn J., Piroth. L., Epaulard O., et al. Persistent COVID-19 symptoms are highly prevalent 6 months after hospitalization: results from a large prospective cohort. Clin Microbiol Infect. 2021 Jul; 27 (7): 1041. e1–1041.e4. DOI: 10.1016/j.cmi.2021.03.012.González-Hermosillo J.A., Martínez-López J.P., Carrillo-Lampón S.A., et al. PostAcute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. Brain Sci. 2021 Jun 8; 11 (6): 760. DOI: 10.3390/brainsci11060760.González-Hermosillo J.A., Martínez-López J.P., Carrillo-Lampón S.A., et al. PostAcute COVID-19 Symptoms, a Potential Link with Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome: A 6-Month Survey in a Mexican Cohort. Brain Sci. 2021 Jun 8; 11 (6): 760. DOI: 10.3390/brainsci11060760.Fortini A., Torrigiani A., Sbaragli S., et al. COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge. Infection. 2021 Oct; 49 (5): 1007–1015. DOI: 10.1007/s15010–021–01638–1.Fortini A., Torrigiani A., Sbaragli S., et al. COVID-19: persistence of symptoms and lung alterations after 3–6 months from hospital discharge. Infection. 2021 Oct; 49 (5): 1007–1015. DOI: 10.1007/s15010–021–01638–1.Karaarslan F., Güneri F. D., Kardeş S. Long COVID: rheumatologic/ musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months. Clin Rheumatol. 2022; 41 (1): 289–296. DOI: 10.1007/s10067–021–05942-x.Karaarslan F., Güneri F. D., Kardeş S. Long COVID: rheumatologic/ musculoskeletal symptoms in hospitalized COVID-19 survivors at 3 and 6 months. Clin Rheumatol. 2022; 41 (1): 289–296. DOI: 10.1007/s10067–021–05942-x.Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 202; 324 (6): 603–605. DOI: 10.1001/jama.2020.12603.Carfì A., Bernabei R., Landi F. Gemelli Against COVID-19 Post-Acute Care Study Group. Persistent Symptoms in Patients After Acute COVID-19. JAMA. 202; 324 (6): 603–605. DOI: 10.1001/jama.2020.12603.Garrigues E., Janvier P., Kherabi Y., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020; 81 (6): e4–e6. DOI: 10.1016/j.jinf.2020.08.029.Garrigues E., Janvier P., Kherabi Y., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J Infect. 2020; 81 (6): e4–e6. DOI: 10.1016/j.jinf.2020.08.029.Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397 (10270): 220–232. DOI: 10.1016/S0140–6736(20)32656–8.Huang C., Huang L., Wang Y., et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021; 397 (10270): 220–232. DOI: 10.1016/S0140–6736(20)32656–8.Moreno-Pérez O., Merino E., Leon-Ramirez J.M., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021; 82 (3): 378–383. DOI: 10.1016/j.jinf.2021.01.004.Moreno-Pérez O., Merino E., Leon-Ramirez J.M., et al. Post-acute COVID-19 syndrome. Incidence and risk factors: A Mediterranean cohort study. J Infect. 2021; 82 (3): 378–383. DOI: 10.1016/j.jinf.2021.01.004.Goërtz Y. M.J., Van Herck M., Delbressine J. M., et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020; 6 (4): 00542–2020. DOI: 10.1183/23120541.00542–2020.Goërtz Y. M.J., Van Herck M., Delbressine J. M., et al. Persistent symptoms 3 months after a SARS-CoV-2 infection: the post-COVID-19 syndrome? ERJ Open Res. 2020; 6 (4): 00542–2020. DOI: 10.1183/23120541.00542–2020.Peghin M., Palese A., Venturini M., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021; 27 (10): 1507–1513. DOI: 10.1016/j.cmi.2021.05.033.Peghin M., Palese A., Venturini M., et al. Post-COVID-19 symptoms 6 months after acute infection among hospitalized and non-hospitalized patients. Clin Microbiol Infect. 2021; 27 (10): 1507–1513. DOI: 10.1016/j.cmi.2021.05.033.Sykes D. L., Holdsworth L., Jawad N., et al. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? Lung. 2021; 199 (2): 113–119. DOI: 10.1007/s00408–021–00423-z.Sykes D. L., Holdsworth L., Jawad N., et al. Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? Lung. 2021; 199 (2): 113–119. DOI: 10.1007/s00408–021–00423-z.Lopez-Leon S., Wegman-Ostrosky T., Perelman C., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021; 11 (1): 16144. DOI: 10.1038/s41598–021–95565–8.Lopez-Leon S., Wegman-Ostrosky T., Perelman C., et al. More than 50 long-term effects of COVID-19: a systematic review and meta-analysis. Sci Rep. 2021; 11 (1): 16144. DOI: 10.1038/s41598–021–95565–8.Petersen M. S., Kristiansen M. F., Hanusson K. D. et al. Long COVID in the Faroe Islands – a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2021; 73 (11): e4058–e4063. DOI: 10.1093/cid/ciaa1792.Petersen M. S., Kristiansen M. F., Hanusson K. D. et al. Long COVID in the Faroe Islands – a longitudinal study among non-hospitalized patients. Clin Infect Dis. 2021; 73 (11): e4058–e4063. DOI: 10.1093/cid/ciaa1792.Ono K., Kishimoto M., Shimasaki T. et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020; 6 (2): e001350. DOI: 10.1136/rmdopen-2020–001350.Ono K., Kishimoto M., Shimasaki T. et al. Reactive arthritis after COVID-19 infection. RMD Open. 2020; 6 (2): e001350. DOI: 10.1136/rmdopen-2020–001350.Gasparotto M., Framba V., Piovella C., et al. Post-COVID-19 arthritis: a case report and literature review. Clin Rheumatol. 2021; 40 (8): 3357–3362. DOI: 10.1007/s10067–020–05550–1.Gasparotto M., Framba V., Piovella C., et al. Post-COVID-19 arthritis: a case report and literature review. Clin Rheumatol. 2021; 40 (8): 3357–3362. DOI: 10.1007/s10067–020–05550–1.Hønge B. L., Hermansen M. F., Storgaard M. Reactive arthritis after COVID-19. BMJ Case Rep. 2021. Vol. 14. Issue 3. P. e241375. DOI: 10.1136/bcr-2020–241375.Hønge B. L., Hermansen M. F., Storgaard M. Reactive arthritis after COVID-19. BMJ Case Rep. 2021. Vol. 14. Issue 3. P. e241375. DOI: 10.1136/bcr-2020–241375.Аронова Е. С., Белов Б. С. Полиартрит, ассоциированный с COVID-19 (клинический случай). Современная ревматология. 2021. № 15. Том 5. С. 76–79. DOI: 10.14412/1996–7012–2021–5–76–79.Aronova E. S., Belov B. S. Polyarthritis associated with COVID-19 (clinical case). Modern rheumatology. 2021. No. 15. Volume 5. P. 76–79. DOI: 10.14412/1996–7012–2021–5–76–79.Derksen V. F., Kissel T., Lamers-Karnebeek F.B. et al. Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Ann Rheum Dis. 2021. Vol. 80. P. 1096–1098. DOI: 10.1136/annrheumdis-2021–219859.Derksen V. F., Kissel T., Lamers-Karnebeek F.B. et al. Onset of rheumatoid arthritis after COVID-19: coincidence or connected? Ann Rheum Dis. 2021. Vol. 80. P. 1096–1098. DOI: 10.1136/annrheumdis-2021–219859.Roongta R., Chattopadhyay A., Ghosh A. Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’ Ann Rheum Dis. 2021. epub ahead of print. DOI: 10.1136/annrheumdis-2021–220479.Roongta R., Chattopadhyay A., Ghosh A. Correspondence on ‘Onset of rheumatoid arthritis after COVID-19: coincidence or connected?’ Ann Rheum Dis. 2021. epub ahead of print. DOI: 10.1136/annrheumdis-2021–220479.Lerma L. A., Chaudhary A., Bryan A., Morishima C., Wener M. H., Fink S. L. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020. Vol. 3. P. 100073. DOI: 10.1016/j.jtauto.2020.100073.Lerma L. A., Chaudhary A., Bryan A., Morishima C., Wener M. H., Fink S. L. Prevalence of autoantibody responses in acute coronavirus disease 2019 (COVID-19). J Transl Autoimmun. 2020. Vol. 3. P. 100073. DOI: 10.1016/j.jtauto.2020.100073.Cares-Marambio K., Montenegro-Jiménez Y. et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021. Vol. 18. P. 14799731211002240. DOI: 10.1177/14799731211002240.Cares-Marambio K., Montenegro-Jiménez Y. et al. Prevalence of potential respiratory symptoms in survivors of hospital admission after coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis. Chron Respir Dis. 2021. Vol. 18. P. 14799731211002240. DOI: 10.1177/14799731211002240.Wu X., Liu X., Zhou Y. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. Vol. 9. Issue 7. P. 747–754. DOI: 10.1016/S2213–2600(21)00174–0.Wu X., Liu X., Zhou Y. et al. 3-month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021. Vol. 9. Issue 7. P. 747–754. DOI: 10.1016/S2213–2600(21)00174–0.Dani M., Dirksen A., Taraborrelli P. et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin med (Lond). 2021. Vol. 21. Issue 1. P. e63–e67. DOI: 10.7861/clinmed.2020–0896.Dani M., Dirksen A., Taraborrelli P. et al. Autonomic dysfunction in 'long COVID': rationale, physiology and management strategies. Clin med (Lond). 2021. Vol. 21. Issue 1. P. e63–e67. DOI: 10.7861/clinmed.2020–0896.George P. M., Barratt S. L., Condliffe R. et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020. Vol. 75. P. 1009–1016. DOI: 10.1136/thoraxjnl-2020–215314.George P. M., Barratt S. L., Condliffe R. et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020. Vol. 75. P. 1009–1016. DOI: 10.1136/thoraxjnl-2020–215314.McMahon D.E., Gallman A. E., Hruza G. J. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021. Vol. 21. Issue 3. P. 313–314. DOI: 10.1016/S1473–3099(20)30986–5.McMahon D.E., Gallman A. E., Hruza G. J. et al. Long COVID in the skin: a registry analysis of COVID-19 dermatological duration. Lancet Infect Dis. 2021. Vol. 21. Issue 3. P. 313–314. DOI: 10.1016/S1473–3099(20)30986–5.Mehta P., Bunker C. B., Ciurtin C. et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect Dis. 2021. Vol. 21. Issue 7. P. 912. DOI: 10.1016/S1473–3099(21)00133-X.Mehta P., Bunker C. B., Ciurtin C. et al. Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. Lancet Infect Dis. 2021. Vol. 21. Issue 7. P. 912. DOI: 10.1016/S1473–3099(21)00133-X.Mohabbat A. B., Mohabbat N. M.L., Wight E. C. Fibromyalgia and chronic fatigue syndrome in the age of COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020. Vol. 4. Issue 6. P. 764–766. DOI: 10.1016/j.mayocpiqo.2020.08.002.Mohabbat A. B., Mohabbat N. M.L., Wight E. C. Fibromyalgia and chronic fatigue syndrome in the age of COVID-19. Mayo Clin Proc Innov Qual Outcomes. 2020. Vol. 4. Issue 6. P. 764–766. DOI: 10.1016/j.mayocpiqo.2020.08.002.Clauw D., Häuser W., Cohen S., Fitzcharles M. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain. 2020. Vol. 161. Issue 8. P. 1694–1697. DOI: 10.1097/j.pain.0000000000001950.Clauw D., Häuser W., Cohen S., Fitzcharles M. Considering the potential for an increase in chronic pain after the COVID-19 pandemic. Pain. 2020. Vol. 161. Issue 8. P. 1694–1697. DOI: 10.1097/j.pain.0000000000001950.Wong T. L., Weitzer D. J. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 2021. Vol. 57. Issue 5. P. 418. DOI: 10.3390/medicina57050418.Wong T. L., Weitzer D. J. Long COVID and myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)-a systemic review and comparison of clinical presentation and symptomatology. Medicina (Kaunas). 2021. Vol. 57. Issue 5. P. 418. DOI: 10.3390/medicina57050418.Graham E. L., Clark J. R.., Orban ZS. et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers”. Ann Clin Transl Neurol. 2021. Vol. 8. Issue 5. P. 1073–1085. DOI: 10.1002/acn3.51350.Graham E. L., Clark J. R.., Orban ZS. et al. Persistent neurologic symptoms and cognitive dysfunction in non-hospitalized Covid-19 “long haulers”. Ann Clin Transl Neurol. 2021. Vol. 8. Issue 5. P. 1073–1085. DOI: 10.1002/acn3.51350.Dotan A., Shoenfeld Y. Post-COVID syndrome: The aftershock of SARS-CoV-2. Int. J. Infect. Dis. 2021; 114: 233–235. DOI: 10.1016/j.ijid.2021.11.020.Dotan A., Shoenfeld Y. Post-COVID syndrome: The aftershock of SARS-CoV-2. Int. J. Infect. Dis. 2021; 114: 233–235. DOI: 10.1016/j.ijid.2021.11.020.Ursini F., Ciaffi J., Mancarella L. et al. Fibromyalgia: a new facet of the postCOVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021. Vol. 7. P. e001735. DOI: 10.1136/rmdopen-2021–001735.Ursini F., Ciaffi J., Mancarella L. et al. Fibromyalgia: a new facet of the postCOVID-19 syndrome spectrum? Results from a web-based survey. RMD Open. 2021. Vol. 7. P. e001735. DOI: 10.1136/rmdopen-2021–001735.Salaffi F., Giorgi V., Sirotti S., Bongiovanni S. et al. The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. Clin. Exp. Rheumatol. 2021; 39: 72–77. PMID: 33200740.Salaffi F., Giorgi V., Sirotti S., Bongiovanni S. et al. The effect of novel coronavirus disease-2019 (COVID-19) on fibromyalgia syndrome. Clin. Exp. Rheumatol. 2021; 39: 72–77. PMID: 33200740.Dinerman H., Goldenberg D. L., Felson D. T. A prospective evaluation of 118 patients with the fibromyalgia syndrome: Prevalence of Raynaud’s phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J. Rheumatol. 1986; 13: 368–373. PMID: 3487650.Dinerman H., Goldenberg D. L., Felson D. T. A prospective evaluation of 118 patients with the fibromyalgia syndrome: Prevalence of Raynaud’s phenomenon, sicca symptoms, ANA, low complement, and Ig deposition at the dermal-epidermal junction. J. Rheumatol. 1986; 13: 368–373. PMID: 3487650.Kötter I., Neuscheler D., Günaydin I., Wernet D., Klein R. Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up. Rheumatol. Int. 2007; 27: 1031–1039. DOI: 10.1007/s00296–007–0413–7.Kötter I., Neuscheler D., Günaydin I., Wernet D., Klein R. Is there a predisposition for the development of autoimmune diseases in patients with fibromyalgia? Retrospective analysis with long term follow-up. Rheumatol. Int. 2007; 27: 1031–1039. DOI: 10.1007/s00296–007–0413–7.Dönmez S., Pamuk Ö. N., Ümit E. G., Top M. Ş. Autoimmune rheumatic disease associated symptoms in fibromyalgia patients and their influence on anxiety, depression and somatisation: A comparative study. Clin. Exp. Rheumatol. 2012; 30: 65–69. PMID: 23137613.Dönmez S., Pamuk Ö. N., Ümit E. G., Top M. Ş. Autoimmune rheumatic disease associated symptoms in fibromyalgia patients and their influence on anxiety, depression and somatisation: A comparative study. Clin. Exp. Rheumatol. 2012; 30: 65–69. PMID: 23137613.Hafiz W., Nori R., Bregasi A., Noamani B., Bonilla D. et al. Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease. Arthritis Res. 2019; 21: 1–11. DOI: 10.1186/s13075–019–2013–9.Hafiz W., Nori R., Bregasi A., Noamani B., Bonilla D. et al. Fatigue severity in anti-nuclear antibody-positive individuals does not correlate with pro-inflammatory cytokine levels or predict imminent progression to symptomatic disease. Arthritis Res. 2019; 21: 1–11. DOI: 10.1186/s13075–019–2013–9.Peker B. O., Şener A. G., Kaptan Aydoğmuş F. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis. J. Immunol. Methods. 2021; 499: 113174. DOI: 10.1016/j.jim.2021.113174.Peker B. O., Şener A. G., Kaptan Aydoğmuş F. Antinuclear antibodies (ANAs) detected by indirect immunofluorescence (IIF) method in acute COVID-19 infection; future roadmap for laboratory diagnosis. J. Immunol. Methods. 2021; 499: 113174. DOI: 10.1016/j.jim.2021.113174.Goebel A., Krock E., Gentry C. et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest. 2021 Jul 7; 131 (13). DOI: 10.1172/JCI144201.Goebel A., Krock E., Gentry C. et al. Passive transfer of fibromyalgia symptoms from patients to mice. J Clin Invest. 2021 Jul 7; 131 (13). DOI: 10.1172/JCI144201.Pascolini S., Vannini A., Deleonardi G. et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci. 2021. Vol. 14. Issue 2. P. 502–508. DOI: 10.1111/cts.12908.Pascolini S., Vannini A., Deleonardi G. et al. COVID-19 and Immunological Dysregulation: Can Autoantibodies be Useful? Clin Transl Sci. 2021. Vol. 14. Issue 2. P. 502–508. DOI: 10.1111/cts.12908.Vlachoyiannopoulos P. G., Magira E., Alexopoulos H. et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020. Vol. 79. P. 1661–1663. DOI: 10.1136/annrheumdis-2020–218009.Vlachoyiannopoulos P. G., Magira E., Alexopoulos H. et al. Autoantibodies related to systemic autoimmune rheumatic diseases in severely ill patients with COVID-19. Ann Rheum Dis. 2020. Vol. 79. P. 1661–1663. DOI: 10.1136/annrheumdis-2020–218009.Litwin C. M., Binder S. R. ANA testing in the presence of acute and chronic infections. J Immunoassay Immunochem. 2016. Vol. 37. Issue 5. P. 439–452. DOI: 10.1080/15321819.2016.1174136.Litwin C. M., Binder S. R. ANA testing in the presence of acute and chronic infections. J Immunoassay Immunochem. 2016. Vol. 37. Issue 5. P. 439–452. DOI: 10.1080/15321819.2016.1174136.Callow K. A., Parry H. F., Sergeant M., Tyrrell D. A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990. Vol. 105. Issue 2. P. 435–446. DOI: 10.1017/s0950268800048019.Callow K. A., Parry H. F., Sergeant M., Tyrrell D. A. The time course of the immune response to experimental coronavirus infection of man. Epidemiol Infect. 1990. Vol. 105. Issue 2. P. 435–446. DOI: 10.1017/s0950268800048019.Liao B., Liu Z., Tang L. et al. Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. Int J Med Sci. 2021. Vol. 18. Issue 1. P. 29–41. DOI: 10.7150/ijms.49728.Liao B., Liu Z., Tang L. et al. Longitudinal clinical and radiographic evaluation reveals interleukin-6 as an indicator of persistent pulmonary injury in COVID-19. Int J Med Sci. 2021. Vol. 18. Issue 1. P. 29–41. DOI: 10.7150/ijms.49728.Marvisi M., Ferrozzi F., Balzarini, et al. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution. Int J Infect Dis. 2020. Vol. 99. P. 485–488. DOI: 10.1016/j.ijid.2020.08.054.Marvisi M., Ferrozzi F., Balzarini, et al. First report on clinical and radiological features of COVID-19 pneumonitis in a Caucasian population: factors predicting fibrotic evolution. Int J Infect Dis. 2020. Vol. 99. P. 485–488. DOI: 10.1016/j.ijid.2020.08.054.Grech S., Borg J. N., Cuschieri S. Back pain: An aftermath of Covid-19 pandemic? A Malta perspective. Musculoskeletal Care. 2021. Epub ahead of print. P. 1–6. DOI: 10.1002/msc.1574.Grech S., Borg J. N., Cuschieri S. Back pain: An aftermath of Covid-19 pandemic? A Malta perspective. Musculoskeletal Care. 2021. Epub ahead of print. P. 1–6. DOI: 10.1002/msc.1574.Kamal M., Abo Omirah M., Hussein A., Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021. Vol. 75. P. e13746. DOI: 10.1111/ijcp.13746.Kamal M., Abo Omirah M., Hussein A., Saeed H. Assessment and characterisation of post-COVID-19 manifestations. Int J Clin Pract. 2021. Vol. 75. P. e13746. DOI: 10.1111/ijcp.13746.Sudre C. H., Murray B., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021. Vol. 27. P. 626–31. DOI: 10.1038/s41591–021–01292-y.Sudre C. H., Murray B., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021. Vol. 27. P. 626–31. DOI: 10.1038/s41591–021–01292-y.UK Office for National Statistics. Prevalence of long COVID symptoms and COVID-19 complications. 2020. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complicationsUK Office for National Statistics. Prevalence of long COVID symptoms and COVID-19 complications. 2020. Available at: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/healthandlifeexpectancies/datasets/prevalenceoflongcovidsymptomsandcovid19complicationsHalpin S. J., McIvor C., Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021. Vol. 93. Issue 2. P. 1013–1022. DOI: 10.1002/jmv.26368.Halpin S. J., McIvor C., Whyatt G. et al. Postdischarge symptoms and rehabilitation needs in survivors of COVID-19 infection: a cross-sectional evaluation. J Med Virol. 2021. Vol. 93. Issue 2. P. 1013–1022. DOI: 10.1002/jmv.26368.Насонов Е. Л., Лила А. М., Мазуров В. И. и др. Коронавирусная болезнь 2019 (COVID-19) и иммуновоспалительные ревматические заболевания. Рекомендации Общероссийской общественной организации «Ассоциация ревматологов России». Научно-практическая ревматология. 2021; 59 (3): 239–254.Nasonov E. L., Lila A. M., Mazurov V. I. et al. Coronavirus disease 2019 (COVID-19) and immunoinflammatory rheumatic diseases. Recommendations of the All-Russian public organization «Association of Rheumatologists of Russia». Scientific and Practical Rheumatology. 2021; 59 (3): 239–254.Методические рекомендации. Особенности течения Long-COVID инфекции. Терапевтические и реабилитационные мероприятия. Под ред. акад. Мартынова А. И. Доступно по ссылке: https://www.rnmot.ru/public/uploads/2022/rnmot/%D0%9C%D0%95%D0%A2%D0%9E%D0%94%D0%98%D0%A7%D0%95%D0%A1%D0%9A%D0%98%D0%95%20%D0%A0%D0%95%D0%9A%D0%9E%D0%9C%D0%95%D0%9D%D0%94%D0%90%D0%A6%D0%98%D0%98.pdfGuidelines. Features of the course of Long-COVID infection. Therapeutic and rehabilitation measures. Ed. acad. Martynova A. I. Available at: https://www.rnmot.ru/public/uploads/2022/rnmot/%D0%9C%D0%95%D0%A2%D0%9E%D0%94%D0%98%D0%A7%D0%95%D0%A1%D0%9A%D0%98%D0%95%20%D0%A0%D0%95%D0%9A%D0%9E%D0%9C%D0%95%D0%9D%D0%94%D0%90%D0%A6%D0%98%D0%98.pdf

The authors declare that there are no conflicts of interest present.